Ceapro Inc V.CZO

Boehringer Ingelheim

[prophetoffactz]

Dr. Kjetil Ask has a paper that was accepted October 13, 2022. It was on the blockbuster drug nintedanib which has been used with PGX. The drug is owned by Boehringer Ingelheim and a long list of scientists from that company co-wrote the paper as highlighted below. Dr. Kjetil Ask keeps very good company when it comes to that drug. The conclusion of the paper: "Our study demonstrates the one of nintedanib's anti-fibrotic mechanisms is to increase IL-4 signaling in macrophages through inhibition of CSF1 receptor resulting in promotion of tissue repair phenotypes."

Anti-Fibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4-associated Tissue Repair Macrophages

 

 

Carolin K Watson , Daniela Schloesser , Katrin Fundel-Clemens , Carmen Lerner , Svenja Gabler , Praveen Baskaran , Christian T Wohnhaas , Stefanie Dichtl , Heinrich J Huber , Kjetil Ask , Florian Gantner , Show All...

-Author Information

• Carolin K Watson Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Immunology + Respiratory , Biberach, Germany
• Daniela Schloesser Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Katrin Fundel-Clemens Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Global Computational Biology, Biberach, Germany
• Carmen Lerner Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Svenja Gabler Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Praveen Baskaran Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Christian T Wohnhaas Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Stefanie Dichtl Max-Planck-Institute of Biochemistry, Martinsried, Bayern, Germany
• Heinrich J Huber Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Kjetil Ask McMaster University, Medicine, HAMILTON, Ontario, Canada
• Florian Gantner Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
• Coralie Viollet Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Matthew J Thomas Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Immunology & Respiratory Diseases Research, Biberach, Germany
• Fidel Ramirez Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany
• Peter J. Murray Max-Planck-Institute of Biochemistry, Martinsried, Bayern, Germany
• Karim C El Kasmi Boehringer Ingelheim Pharma GmbH and Co KG Forschungs- und Entwicklungs-Standort Biberach, Biberach, Baden-Wrttemberg, Germany

Anti-Fibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4-associated Tissue Repair Macrophages | American Journal of Respiratory Cell and Molecular Biology | Articles in Press (atsjournals.org)